Mănescu Ion-Bogdan, Pál Krisztina, Lupu Silvia, Dobreanu Minodora
Clinical Laboratory, County Emergency Clinical Hospital of Targu Mures, 540136 Targu Mures, Romania.
Department of Laboratory Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, 540142 Targu Mures, Romania.
Life (Basel). 2022 Dec 15;12(12):2112. doi: 10.3390/life12122112.
Atherosclerosis is the main cause of cardiovascular disease worldwide. The progression of coronary atherosclerosis leads to coronary artery disease, with impaired blood flow to the myocardium and subsequent development of myocardial ischemia. Acute coronary syndromes and post-myocardial infarction heart failure are two of the most common complications of coronary artery disease and are associated with worse outcomes. In order to improve the management of patients with coronary artery disease and avoid major cardiovascular events, several risk assessment tools have been developed. Blood and imaging biomarkers, as well as clinical risk scores, are now available and validated for clinical practice, but research continues. The purpose of the current paper is to provide a review of recent findings regarding the use of humoral biomarkers for risk assessment in patients with heart disease.
动脉粥样硬化是全球心血管疾病的主要病因。冠状动脉粥样硬化的进展会导致冠状动脉疾病，使心肌血流受损，进而引发心肌缺血。急性冠状动脉综合征和心肌梗死后心力衰竭是冠状动脉疾病最常见的两种并发症，且与更差的预后相关。为了改善冠状动脉疾病患者的管理并避免重大心血管事件，已开发了多种风险评估工具。血液和影像生物标志物以及临床风险评分现已可供临床实践使用并得到验证，但研究仍在继续。本文的目的是综述关于使用体液生物标志物对心脏病患者进行风险评估的最新研究结果。
